Why it matters: ASX-listed CSL is the world’s third-largest biotech group
Underlying earnings rose 20 per cent with a strong rebound at CSL Behring
CSL declared a final dividend of $US1.29 a share, making $US2.36 in total
Australia’s premier biotech CSL has shrugged off doubts it can rebound from pandemic challenges to its core business after lifting full-year profit 10 per cent to $US2.61 billion ($4 billion) and embarking on a plan to boost the yield of its key raw material – immunoglobulin.
The $133 billion blood products giant says it will attempt to boost the yield of immunoglobulin from human blood plasma after surging sales of blockbuster therapies made from the protein helped put its earnings back on their customary growth track.
Loading...
Ben Potter was a senior writer at The Australian Financial Review.
